Evidence map›Paper›PMID 9327730›Full record

ArticleThe American journal of pathology1997

Selective deposits of versican in the extracellular matrix of restenotic lesions from human peripheral arteries.

T N Wight, S Lara, R Riessen, R Le Baron, J Isner

Abstract read
In one paragraph

Article in The American journal of pathology, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 81 citations in OpenAlex.

  1. Article
  2. V3: an enigmatic isoform of the proteoglycan versican.American journal of physiology. Cell physiology · 2023
    Review
  3. Article
  4. Extracellular matrix dynamics in vascular remodeling.American journal of physiology. Cell physiology · 2020
    Review
  5. Article
  6. Arteriosclerosis, thrombosis, and vascular biology · 2019
    Article
  7. A role for proteoglycans in vascular disease.Matrix biology : journal of the International Society for Matrix Biology · 2018
    Review
  8. Provisional matrix: A role for versican and hyaluronan.Matrix biology : journal of the International Society for Matrix Biology · 2017
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Hyaluronan-dependent pericellular matrix.Advanced drug delivery reviews · 2007
    Review
  15. Article
  16. Versican degradation and vascular disease.Trends in cardiovascular medicine · 2006
    Review
  17. Accumulation and loss of extracellular matrix during shear stress-mediated intimal growth and regression in baboon vascular grafts.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2005
    Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

T N WightDepartment of Pathology, University of Washington, Seattle 98195, USA.
S Lara
R Riessen
R Le Baron
J Isner
University of Washington · US

Funding

VLA-4 and VCAM-1 in Advanced AtherosclerosisP01HL018645 · NHLBI · UNIVERSITY OF WASHINGTON · PI HARLAN, JOHN MARSHALL · 1985 to 2010
$23.9M
Therapeutic Angiogenesis in Vascular Medicine IVR01HL053354 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI KISHORE, RAJ · 1995 to 2015
$4.2M
THERAPEUTIC ANGIOGENESIS IN VASCULAR MEDICINE IIR37HL053354 · NHLBI · CARITAS ST. ELIZABETH'S MEDICAL CENTER · PI ISNER, JEFFREY · 2000 to 2001
$726k
NHLBI NIH HHS HL02824NHLBI NIH HHS HL18645NHLBI NIH HHS HL53354
6 · The paper itself

Abstract

Although a large percentage of the volume of human restenotic arterial lesions is occupied by extracellular matrix (ECM), the composition and organization of this ECM are not well characterized. In this study, restenotic segments taken from 30 human peripheral arteries by directional atherectomy at times ranging from 13 days to 36 months after angioplasty were analyzed for specific patterns of ECM composition and organization by light and electron microscopic histochemistry and immunohistochemistry. Histochemical analysis revealed the presence of distinct zones, enriched either in proteoglycans or fibrillar collagen. Most sections contained these regions juxtaposed to each other. The frequency of these two distinct ECMs did not change as a function of time after angioplasty. The collagen-rich zone usually contained elongated smooth muscle cells spaced close together except in regions resembling fibrous plaques. The proteoglycan-rich ECM contained both elongated and stellate-shaped smooth muscle cells randomly arranged and separated by wide distances. This region resembled the loose-connective-tissue-containing myxoid region typical of restenotic lesions. Immunohistochemical analysis of these regions revealed that the proteoglycan-containing zone stained intensely for versican, a large interstitial chondroitin sulfate proteoglycan, whereas the collagen-containing areas were mostly negative for versican but positive for type I collagen. The versican-positive regions also immunostained for biglycan, a small leucine-rich dermatan sulfate proteoglycan, and sparsely for elastin. However, both of these ECM molecules were present in the versican-negative type I collagen-positive regions of the lesions. These results suggest that the development of restenotic lesions involves localized deposits of specific ECM molecules that may play a role in the asymmetric renarrowing of this tissue after angioplasty.

Indexed as

Angioplasty, BalloonArterial Occlusive DiseasesArteriesChondroitin Sulfate ProteoglycansExtracellular MatrixHumansImmunohistochemistryLectinsLectins, C-TypePeripheral Vascular DiseasesProteoglycansRecurrenceVersicansChondroitin Sulfate ProteoglycansLectinsLectins, C-TypeProteoglycansVCAN protein, humanVersicans

Identifiers

PMID9327730
PMCPMC1858059
OpenAlexW66938950

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.